Investments
43Portfolio Exits
3Funds
7About Brandon Capital Partners
Brandon Capital Partners makes seed and venture capital investments to support the development and international growth of Australian life science companies. The firm works collaboratively with entrepreneurs to demonstrate the benefit of their technology, thereby creating value for them, their teams and investors.
Brandon Capital Partners Headquarter Location
Level 1 257 Collins Street
Melbourne, Victoria, 3000,
Australia
+61 3 9657 0700
Expert Collections containing Brandon Capital Partners
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Brandon Capital Partners in 1 Expert Collection, including Pharma Startups.
Pharma Startups
5,090 items
Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.
Latest Brandon Capital Partners News
Sep 16, 2021
Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced the completion of its oversubscribed $60M Series C financing, led by Arboretum Ventures. Participating in the round were NEA, Temasek, Pavilion Capital, Brandon Capital Partners, Vertex Growth, Vertex Ventures HC, and WTT Investment Ltd. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
Brandon Capital Partners Investments
43 Investments
Brandon Capital Partners has made 43 investments. Their latest investment was in Allay Therapeutics as part of their Series C on September 9, 2021.
Brandon Capital Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/15/2021 | Series C | Allay Therapeutics | $60M | Yes | Arboretum Ventures, New Enterprise Associates, Pavilion Capital, Temasek Holdings, Vertex Growth, Vertex Ventures HC, and WTT Investment | 6 |
7/13/2021 | Seed VC | Amaroq Therapeutics | $9.7M | Yes | 1 | |
6/30/2021 | Series A | Currus Biologics | $7.5M | Yes | 3 | |
6/16/2021 | Seed VC - II | |||||
11/16/2020 | Seed VC |
Date | 9/15/2021 | 7/13/2021 | 6/30/2021 | 6/16/2021 | 11/16/2020 |
|---|---|---|---|---|---|
Round | Series C | Seed VC | Series A | Seed VC - II | Seed VC |
Company | Allay Therapeutics | Amaroq Therapeutics | Currus Biologics | ||
Amount | $60M | $9.7M | $7.5M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | Arboretum Ventures, New Enterprise Associates, Pavilion Capital, Temasek Holdings, Vertex Growth, Vertex Ventures HC, and WTT Investment | ||||
Sources | 6 | 1 | 3 |
Brandon Capital Partners Portfolio Exits
3 Portfolio Exits
Brandon Capital Partners has 3 portfolio exits. Their latest portfolio exit was Elastagen on February 07, 2018.
Brandon Capital Partners Fund History
7 Fund Histories
Brandon Capital Partners has 7 funds, including MRCF5.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
4/29/2019 | MRCF5 | $147.67M | 2 | ||
7/26/2016 | Medical Research Commercialization Fund III | ||||
5/20/2015 | Medical Research Commercialisation Fund III | ||||
6/30/2012 | MRCF IIF Partnership LP | ||||
6/30/2009 | Brandon Biosciences Fund No 1 |
Closing Date | 4/29/2019 | 7/26/2016 | 5/20/2015 | 6/30/2012 | 6/30/2009 |
|---|---|---|---|---|---|
Fund | MRCF5 | Medical Research Commercialization Fund III | Medical Research Commercialisation Fund III | MRCF IIF Partnership LP | Brandon Biosciences Fund No 1 |
Fund Type | |||||
Status | |||||
Amount | $147.67M | ||||
Sources | 2 |
Brandon Capital Partners Team
5 Team Members
Brandon Capital Partners has 5 team members, including current Chief Financial Officer, Kerensa Argyriou.
Name | Work History | Title | Status |
|---|---|---|---|
Kerensa Argyriou | Helmsman Capital | Chief Financial Officer | Current |
Michael Ball | Chief Financial Officer | Current | |
David Fisher | Founding Partner | Current | |
Stephen Thompson | Founding Partner | Current | |
Chris Nave | Melbourne Ventures | Managing Director | Current |
Name | Kerensa Argyriou | Michael Ball | David Fisher | Stephen Thompson | Chris Nave |
|---|---|---|---|---|---|
Work History | Helmsman Capital | Melbourne Ventures | |||
Title | Chief Financial Officer | Chief Financial Officer | Founding Partner | Founding Partner | Managing Director |
Status | Current | Current | Current | Current | Current |